J&J Q3 Pharma Sales Beat Expectations, Full-Year EPS Guidance Raised to $11.10
nashnova research
Johnson & Johnson posted Q3 non-GAAP EPS of $2.59, beating estimates by $0.06, as pharma revenue grew 7.7% and the company lifted full-year profit guidance — shares rose ~1% after hours.
How big was the beat?
Non-GAAP EPS came in at $2.59, topping consensus by $0.06; revenue hit $25.4 billion, up 5.8% year-on-year, roughly in line with estimates.
Full-year adjusted EPS guidance midpoint was raised to $11.10, up ~$0.06 from the prior range and implying ~2.9% year-on-year growth.
This means → the beat was driven by profits, not revenue — drug sales were strong and cost discipline added the extra margin.
Which drugs drove the surge?
Autoimmune drug Tremfya grew 68% year-on-year, ahead of analyst estimates; psychiatric drug Caplyta grew 66% as prescriptions for its new indication — adjunctive depression treatment — began to ramp.
Multiple myeloma — a blood cancer — drug Tecvayli grew nearly 77%; flagship Darzalex delivered double-digit growth but slightly missed estimates.
Oral psoriasis drug Icotyde has not disclosed standalone sales yet, but CFO Joe Wolk said 20,000 patients have received prescriptions.
In plain terms = several new drugs are all inflecting at once, each growing above 60% — that breadth of acceleration is rare for a pharma major.
Why did med-tech lag behind?
The medical-devices segment grew just 2.5% year-on-year, well behind pharma.
CFO Wolk was blunt: "The med-tech business frankly needs to improve." He pointed to Middle East geopolitical disruption and fiscal austerity in parts of Europe.
This reflects a widening split inside J&J — the pharma leg is sprinting while the devices leg is slowing.
Will J&J sell or spin off orthopedics?
Bloomberg previously reported that Apollo Global Management is in talks to acquire J&J's orthopedics unit at a valuation near $20 billion, though a deal could still fall apart.
Wolk said the company currently "leans toward a straight spin-off" rather than a sale, calling it "the best way to create value and the most likely path forward."
Separately, J&J's Ottava soft-tissue robotic surgery system won FDA clearance in July, marking its entry into the surgical-robotics market.
This means → J&J is pruning low-growth orthopedics to concentrate resources on robotic surgery and high-growth pharma.
What does this signal for the sector?
J&J is typically one of the first major pharma companies to report each quarter, making its results a bellwether for the industry.
This quarter's beat suggests large pharma is navigating U.S. federal policy shifts and FDA leadership turnover without significant disruption.
In plain terms = J&J handed in its paper first, and the grade looks solid — whether peers can sustain that momentum is the market's next checkpoint.
市场有风险，内容仅供研究参考，不构成投资建议。